Annual report pursuant to Section 13 and 15(d)

Collaboration Agreements, License and Other Research and Development Agreements (Details Narrative)

v3.22.0.1
Collaboration Agreements, License and Other Research and Development Agreements (Details Narrative) - USD ($)
12 Months Ended
Nov. 19, 2021
Nov. 19, 2020
Dec. 12, 2019
Apr. 16, 2019
Feb. 19, 2016
Dec. 31, 2021
Dec. 31, 2020
Dec. 13, 2019
Apr. 02, 2019
Research and Development Expense           $ 14,583,283 $ 14,358,918    
Revenue from Contract with Customer, Excluding Assessed Tax           33,333 158,333    
Cooperative Research And Development Agreements [Member]                  
Remaining balance lease term amount         $ 200,000        
Debt Instrument, Term       3 years          
Other Commitment       $ 200,000          
Funds provide for support                 $ 157,405
Cystic Fibrosis Foundation [Member]                  
Proceeds from Collaborators           2,500,000      
Genentech [Member]                  
Revenue from Contract with Customer, Excluding Assessed Tax           33,000      
Award Agreement [Member] | Cystic Fibrosis Foundation [Member]                  
Therapeutics development award   $ 4,200,000              
Proceeds from award   484,249              
[custom:AdditionalMilestonePayment] $ 321,000                
Royalty payable   21,200,000              
Research and Development Expense           2,200,000 100,000    
Award Agreement [Member] | Cystic Fibrosis Foundation [Member] | Upon Achievement Of Sales Milestones [Member]                  
Royalty payable   $ 4,200,000              
Award Agreement [Member] | Cystic Fibrosis Foundation [Member] | Prepaid Expenses and Other Current Assets [Member]                  
Grants Receivable             650,000    
Award Agreement [Member] | Cystic Fibrosis Foundation [Member] | Accrued Expense And Other Current Liabilities [Member]                  
Other Liabilities             $ 899,000    
Genentech Feasibility Study Agreement [Member] | Genentech [Member]                  
Agreement description     Genentech shall pay to the Company a total of $100.0 thousand for three molecules, or approximately $33 thousand per molecule, which will be recognized upon the Company fulfilling its obligations for each molecule under the Agreement.            
Deferred Revenue               $ 100,000  
License Agreement [Member]                  
Milestone fee           100,000      
Taxes and Licenses           $ 50,000